BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11970740)

  • 1. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
    Pegram MD; O'Callaghan C
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D; Pegram M
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
    Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
    Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK.
    Papazisis KT; Habeshaw T; Miles DW;
    Int J Clin Pract; 2004 Jun; 58(6):581-6. PubMed ID: 15311558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1491-502. PubMed ID: 23982598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
    Ligibel JA; Winer EP
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
    Coudert BP; Arnould L; Moreau L; Chollet P; Weber B; Vanlemmens L; Moluçon C; Tubiana N; Causeret S; Misset JL; Feutray S; Mery-Mignard D; Garnier J; Fumoleau P
    Ann Oncol; 2006 Mar; 17(3):409-14. PubMed ID: 16332965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
    Antón A; Ruiz A; Plazaola A; Calvo L; Seguí MA; Santaballa A; Muñoz M; Sánchez P; Miguel A; Carrasco E; Lao J; Camps J; Alfaro J; Antolín S; Cámara MC
    Ann Oncol; 2011 Jan; 22(1):74-79. PubMed ID: 20603435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
    Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
    J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
    Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
    Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
    Nabholtz JM; Gligorov J
    Expert Opin Pharmacother; 2005 Aug; 6(9):1555-64. PubMed ID: 16086643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of chemotherapy by anti-HER.
    Kataoka A; Ishida M; Murakami S; Ohno S
    Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.